|Specificity:||The antibody MEM-97 reacts with CD20 (Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on B lymphocytes (it is lost on plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes.
HLDA V; WS Code B CD20.9
|Immunogen:||Raji human Burkitt's lymphoma cell line|
|Species Reactivity:||Human, Porcine, Bovine|
Recommended dilution:10 μg/ml
|Purity:||> 95% (by SDS-PAGE)|
|Purification:||Purified by protein-A affinity chromatography|
|Storage Buffer:||Azide free phosphate buffered saline (PBS), approx. pH 7.4; 0.2 μm filter sterilized.|
|Storage / Stability:||Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.|
|Expiration:||See vial label|
|Lot Number:||See vial label|
|Background:||CD20 is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.|
*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
*Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S: Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 1996 Oct 1;157(7):2939-46.
*Polyak MJ, Deans JP: Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002 May 1;99(9):3256-62.
*Brdicková N, Brdicka T, Angelisová P, Horváth O, Spicka J, Hilgert I, Paces J, Simeoni L, Kliche S, Merten C, Schraven B, Horejsí V: LIME: a new membrane Raft-associated adaptor protein involved in CD4 and CD8 coreceptor signaling. J Exp Med. 2003 Nov 17;198(10):1453-62.
*Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross-reactive anti-human monoclonal antibodies as a tool for B-cell identification in dogs and pigs. Vet Immunol Immunopathol. 2007 Sep 15;119(1-2):56-62.
*Strobl H, Takimoto M, Majdic O, Fritsch G, Scheinecker C, Höcker P, Knapp W: Myeloperoxidase expression in CD34+ normal human hematopoietic cells. Blood. 1993 Oct 1;82(7):2069-78.
For laboratory research only, not for drug, diagnostic or other use.
EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic